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Abstract
Background: MetabERN is one of the 24 European Reference Networks created according to the European Union
directive 2011/24/EU on patient’s rights in cross border healthcare. MetabERN associates 69 centres in 18 countries,
which provide care for patients with Hereditary Metabolic Diseases, and have the mission to reinforce research and
provide training for health professionals in this field. MetabERN performed a survey in December 2017 with the aim
to produce an overview documenting research activities and potentials within the network. As the centres are
multidisciplinary, separated questionnaires were sent to the clinical, university and laboratory teams. Answers
were received from 52 out of the 69 centres of the network, covering 16 countries. A descriptive analysis of
the information collected is presented.
Results: The answers indicate a marked interest of the respondents for research, who expressed high motivation and
commitment, and estimated that the conditions to do research in their institution were mostly satisfactory. They are
active in research, which according to several indicators, is competitive and satisfies standards of excellence, as well as
the education programs offered in the respondent’s universities. Research in the centres is primarily performed in
genetics, pathophysiology, and epidemiology, and focuses on issues related to diagnosis. Few respondents declared
having activity in human and social sciences, including research on patient’s quality of life, patient’s awareness, or
methods for social support. Infrastructures offering services for medical research were rarely known and used
by respondents, including national and international biobanking platforms. In contrast, respondents often
participate to patient registries, even beyond their specific field of interest.
Conclusions: Taken as a whole, these results provide an encouraging picture of the research capacities and activities
in the MetabERN network, which, with respect to the number and representativeness of the investigated centres, gives
a comprehensive picture of research on Hereditary Metabolic Diseases in Europe, as well as the priorities for future
actions. Marginal activity in human and social sciences points out the limited multidisciplinary constitution of the
responding teams with possible consequences on their current capability to participate to patient’s empowerment
programs and efficiently collaborate with patient’s advocacy groups.
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Background
The European Union (EU) directive 2011/24/EU on pa-
tient’s rights in cross-border healthcare enables patients to
be reimbursed for treatment in another EU Member State
[1]. It facilitates the access of patients to information on
healthcare and thus increases their treatment options. It
provides patients with the best treatment and advice avail-
able in the EU for their specific condition, and provides
healthcare professionals (HCPs) with access to a highly spe-
cialized pool of colleagues from all over Europe. The direct-
ive is especially relevant for rare and complex diseases,
which affect around 30 million people in the EU. Article 12
of the directive created the European Reference Networks
(ERNs) between HCPs and centres of expertise in the
Member States in the area of rare diseases [2, 3]. ERNs are
intended to concentrate resources, to pool knowledge and
spread best practices, to exploit innovations in medical sci-
ence and health technologies, and to improve diagnosis and
the delivery of healthcare especially in Member States with
an insufficient number of patients with a particular medical
condition or lacking technology or expertise to pro-
vide highly specialized services. In addition, ERNs have
the mission to reinforce research in all its aspects,
clinical, preclinical, epidemiological, diagnostic, thera-
peutics, social sciences [4], and to provide training
for health professionals. Twenty-four ERNs working
on a range of thematic issues became operational in
2017. They comprise more than 900 highly specialized
healthcare units located in 313 hospitals in 25 Mem-
ber States (plus Norway).
MetabERN (https://metab.ern-net.eu/) is the network
specifically dedicated to Hereditary Metabolic Diseases
(HMDs). There are more than 1000 rare HMDs [5] belong-
ing to 7 subgroups: 1) Amino and organic acids related dis-
orders (AOA); 2) Disorders of pyruvate metabolism, Krebs
cycle defects, mitochondrial oxidative phosphorylation dis-
orders, disorders of thiamine transport and metabolism
(PM-MD); 3) Carbohydrate, fatty acid oxidation and ketone
bodies disorders (C-FAO); 4) Lysosomal disorders (LSD); 5)
Peroxisomal and lipid related disorders (PD); 6) Congenital
disorders of glycosylation and disorders of intracellular traf-
ficking (CDG); and 7) Disorders of neuromodulators and
small molecules (NOMS). MetabERN associates 69 centres
in 17 Member States plus Norway (see the list in Additional
file 1), mostly belonging to University hospitals, in which
1671 professionals follow more than 40,000 patients, of
whom two-third are children.
As a first step in implementing its research mission,
MetabERN performed a survey in December 2017. The
primary aim was an overview documenting research activ-
ities and potentials within the 69 centres of the network.
Since the MetabERN centres comprise multidisciplinary
teams, declarations were collected by proper figures such
as University professors, laboratory heads and heads of
research units, according to the need. The secondary aim
of the study was to identify the strengths and the weak-
nesses of research on HMDs in the network. With respect
to the size and presumed representativeness of the investi-
gated centres, the survey was intended to contribute to
mapping research activity in the field of HMDs in the EU.
Results
We received answers from 52 out of the 69 centres of
the network, covering 16 out of the 18 countries partici-
pating to MetabERN (Additional file 1: Table S1). An-
swers were not uniformly received from the three
contacted groups of each centre (the clinical group, the
university group, and the laboratory group, see the
methods section) and some groups sent several answers
(Additional file 1: Table S1). We received a total of 148
responses to the 207 invitations sent to participate to
the survey (66%). They included 52, 52 and 44 responses
for the clinical, university and laboratory groups, re-
spectively. The questions and multiple answers choice
questionnaires are shown as Additional file 1. However,
not all respondents completed the entire questionnaire.
The analysis of each individual question was performed
according to the number of complete responses to each
question, which varies from one question to another.
Research and teaching in the host institution
Questions related to personal research and teaching ac-
tivity, and research and teaching in the host institution,
were answered by 113 participants (clin. 35, univ. 43,
lab. 35). Almost all respondents were active in research
(clin. 97%, univ. 85%, lab. 100%) and had published at
least one article in an ISI-referenced journal during the
last 3 years. These publications associated international
collaborators (> 40%) and/or collaborators from other
national institutions (> 50%).
Investigators in the clinical group answered questions
about financial support (n = 43) indicating that they re-
ceive national (40/43) and/or international (30/43)
grants, to which many of them have applied as the study
coordinator (international: 60%, national: 90%, n = 43).
Institutional funding by the government is another im-
portant resource (38/43), as well as contracts with the
industry (37/43). Collaborative research with the indus-
try is a common practice for investigators in the clinical
group (77% are engaged with an international company,
65% with a national company, n = 35), whereas this is
more occasional for investigators in the university group
(42% international and national, n = 43).
Almost all participants declared that their implication
in research satisfies personal motivation to get more ex-
pertise. The main perceived barrier to do research is
unanimously the lack of time due to high clinical work-
load, followed by insufficient funding. However, centres
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in which rotational positions for clinicians or researchers
are organized remain minority (40 and 37% for clinicians
and researchers, respectively). Nevertheless, physicians
are involved in research in 94% of the clinical groups
(most often more than 4 clinicians in the group partici-
pate, n = 37), as compared to 72% for the professors, 68%
for the PhDs and 50% for the nurses (on average, one to
three persons for each of these categories are involved).
Participants in the clinical group estimate that research
performed in their institution reaches international (36/37)
and national (36/37) standards with respect to excellence,
that it contributes to local/regional development (33/37), to
the quality of teaching (33/37), and increases the attractive-
ness of the institution (35/37), the contacts with industry
(32/37), as well as the networking activities (33/37) and the
implementation of quality assurance processes (33/37).
Answers received from the clinical departments (n = 35)
also indicate that their host institutions award doctorates
(29/35), some offering teaching in English (19/35) and the-
ses defended in English (21/35), with interdisciplinary
PhD programs (29/35) comprising mobility (28/35), stu-
dent exchanges (21/35) and sometime international joint
doctoral programs (16/35).
Research activity of the centres
The survey collected 122 answers related to the main
areas and fields of research in the responding centres
(clin. 42, univ. 45, lab. 35). Figure 1 shows the number
of responses indicating high or relatively high activity in
a specific field.
Research in genetic and pathophysiology is the most
active field (108/122, Fig.1a), with a strong predomin-
ance of genetics (gene identification 95/122, Fig. 1b) and
genomics (high throughput genomics 80/122, Fig. 1b).
These activities rely on sampling and data collection
(biobanking 69/122, database for omics 67/122, omics
technologies 63/122, Fig. 1b) and benefit from shared
platforms (for biobanking 64/122, for genomic and
proteomic 66/122, Fig. 1f ), and to local bioinformatics
facilities (60/122, Fig. 1b) rather than shared bioinfor-
matics platforms (36/122, Fig. 1f ). Activities in imaging
and microscopy (64/122, Fig. 1b) and search for new
animal models (63/122, Fig. 1b) indicate interest for re-
search in pathophysiology in about one-half of the
responding teams.
The second most active field of activity is therapeutic
research (94/122, Fig. 1a), with a slight predominance of
investigational studies (81/122, Fig. 1c) over therapeutic
phase I/II studies (65/122, Fig. 1c), or phase III trials
sponsored by industry (69/122, Fig. 1c). The specific
fields of research on transplantation (68/122, Fig.1c),
medical devices (50/122, Fig. 1c), or surgical procedures
(53/122, Fig. 1c) are each dealt with in about one-half of
the responding teams. Few among the responding teams
are concerned by research in bio-production (18/122,
Fig.1c; GMP platform 35/122, Fig.1h).
Epidemiology is an active field of research in the Meta-
bERN network (79/122, Fig.1a), with marked interest for
all aspects of the discipline relevant to rare diseases. The
constitution of registries (97/122, Fig.1d) and cohorts
(80/122, Fig.1d) benefits from dedicated platforms (regis-
tries 76/122, long-term cohorts 80/122, Fig. 1h). They
are used for the definition of biomarkers (96/122, Fig.1d)
or other methods for diagnosis and prognosis (85/122,
Fig.1d), as well as to identify new (78/122, Fig.1d) and/or
ultra rare (79/122, Fig.1d) diseases.
Preclinical research in in vitro or in animal models
with the purpose of potential therapeutic applications is
performed in many of the responding teams (72/122,
Fig.1a), although each thematic issue concerns a minor-
ity of the teams. They include investigations aimed at
defining therapeutic targets (50/122, Fig.1g), therapeutic
methods (biotechnology research 50/122, Fig.1g), or pro-
ducing proof of concept (50/122, Fig.1g). The less active
fields concern research on therapeutic chemicals (search
for activity, drug screening, toxicology: ≤40/122, Fig. 1e
and Fig. 1h).
A large proportion of the responding teams is inter-
ested in various aspects of research on health systems
(60/122, Fig.1a). These include the validation of methods
for diagnostic screening (87/122, Fig.1e), or the elabor-
ation of research policies (guidelines, national plans,
health care resources, 85/122, Fig.1e). However, only a
minority of the responding teams declared activity in
cost analysis studies, health technology assessment, or
e-health (45/122, 39/122, 53/122, respectively, Fig. 1e).
The less active research activity domain of the responding
teams concerns human and social sciences (37/122, Fig.1a).
Activity is low in all aspects, and especially marginal for re-
search aimed at investigating the patient’s quality of life and
its determinants (society and rare diseases 41/122, methods
to support quality of life 49/122, Fig.1f). Slightly more activ-
ity was declared in the fields of care practices, patient
awareness and health care policies and innovation (61/122,
64/122, 53/122 and 56/122, respectively, Fig.1f).
Collaboration with international research infrastructures
and organizations
The survey comprised questions referring to knowledge
about the existence of various international research orga-
nizations and collaboration with these organizations. We
received 106 answers (clin. 34, univ. 42, lab. 30, Table 1).
The first set of questions concerned collaborations with
the international research infrastructures supported by the
European Scientific Forum on Research Infrastructures
(ESFRI) [6], which proposes services for biomedical re-
search. Services concern biobanking (BBMRI), transla-
tional research (EATRIS), clinical research (ECRIN),
Heard et al. Orphanet Journal of Rare Diseases          (2019) 14:119 Page 3 of 9
a e
b f
c g
d h
Fig. 1 Numbers of responses indicating « high », or « rather high » activity in the indicated field out of 122 answers
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bioinformatics (ELIXIR), drug screening (OPENSCREEN),
imaging (EUROBIO-IMAGING), transgenic animals re-
pository (INFRAFRONTIERS), system biology (ISBE), and
a micro-organisms repository (MIRRI). Answers showed
comparable scores for the clinical, university and labora-
tory groups, which indicated that a large majority of the
responding centres do not know about the existence of
these infrastructures, and even when they know them,
they very rarely collaborate with them (Table 1). An add-
itional question concerning 18 national biobanking infra-
structures (list in Additional file 1) revealed that in the
best case, 47 of the 106 respondents knew about the ser-
vice and 8 collaborated with it. The large majority of the
others national biobanks were not known.
In contrast, responding teams are well aware of
the existence of patient registries, even beyond their
specific field of interest (Table 1), and actively par-
ticipate in the constitution of these registries. Clin-
ical teams, university teams, and laboratory teams
expressed equal level of interest.
Teams were also asked whether they are aware of the
existence of international scientific organizations rele-
vant to rare diseases and participate to their activities
(Table 1). Questions concerned EURORDIS (a non-gov-
ernmental patient-driven alliance of patient organiza-
tions), ISNS (the International Society for Neonatal
Screening), SSIEM (the Society for the Study of Inborn
Errors of Metabolism), SIMD (the Society for Inherited
Metabolic Diseases), ERNDIM (the European Research
Network for the Diagnosis of Inherited disorders of the
Metabolism), and IRDIRC (the International Rare Dis-
ease Research Consortium). All these organizations are
Table 1 Numbers of positive responses out of 106 received responses to the questions « do you know » and « do you collaborate
with» the following organizations. Full names and/or field of activity of the listed organizations are given in the text
Number of positive answers
Organization Known Collaboration
ESFRI Infrastructures BBMRI 55 14
EATRIS 33 4
ECRIN 51 8
ELIXIR 37 2
OPENSCREEN 23 0
EUROBIOIMAGING 29 1
INFRAFRONTIER 15 0
ISBE 24 1
MIRRI 13 1
Registries E---HOD (homocystinurias, methylation) 66 39
EIMD 65 37
Euroglycanet 54 10
ICG Gaucher reg. 58 18
Pompe 43 21
MPS I reg. 53 43
International PMSI reg. 62 19
Hunter Outcome survey 58 39
International Morquio reg. 55 20
lInternationa Niemann---Pick reg. 61 20
Fabry Outcome survey 60 30
International Fabry reg. 66 20
Galactosemia patient reg. 53 29
International organisations EURORDIS 87 27
ISNS 53 15
SSIEM 93 71
SIMD 55 15
ERNDIM(QI) 75 40
IRDIRC 61 18
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known by a majority of the responding centres, and
many of them actively participate.
Discussion
This report presents a descriptive analysis of the informa-
tion collected through a cross-sectional on-line survey
performed in December 2017 by MetabERN. According
to the missions attributed to the ERNs by the EU
cross-border healthcare directive 2011/24 to reinforce
medical research in their thematic field, the survey was
conducted to get insights into the research activities and
capabilities of the members of the MetabERN network.
The target audience comprised all of the 69 centres par-
ticipating in MetabERN, which were designated by the
European Commission (DG Sante) as the reference cen-
tres for health care delivery in the field of HMDs in Eur-
ope [7]. Three-fourth of the centres (52/69) responded to
the survey. These centres are in essence multidisciplinary
and reputed as centers of excellence for care, teaching and
research in the field of HMDs. The survey therefore pro-
vides insight into the centres that offer the best cares,
diagnosis, treatments and advices patients with HMDs
can find in Europe in the context of the cross-border
healthcare directive.
The number of centres participating to the survey and
their presumed representativeness as reference centres
for HMDs, support the idea that the collected informa-
tion is relevant to the EU as a whole. However, not all
EU countries participate to MetabERN, the number of
MetabERN centres largely varies between countries, and
some centres sent several responses to the survey (18/
154 answers). These facts represent possible bias and
limit the representativeness of the study. It is also im-
portant to take into account that this study, as a survey,
relies on self-declarations. Appropriate interpretation
should therefore confront the subjective picture emer-
ging from this study with objective data, such as can be
obtained from funding agencies, or institutional or na-
tional evaluation bodies.
Questionnaires sent to the centres (shown as Additional
file 1) contained multiple choices questions related to the
medical research performed by individuals in their re-
spective institutions and countries. Questions referred to
the level of research activity and the type of research, with
an additional focus on awareness and collaboration with
national, European, and international medical research fa-
cilities and organizations. Due to the centres’ multidiscip-
linary teams the questions were adapted to the clinical,
university and laboratory teams specific interests.
The high response rate is an indication of the marked
interest for research among the respondents. They
expressed high motivation and commitment to do re-
search, and indicated that the research conditions of
their institution were mostly satisfactory. Respondents
were actively contributing to research activities, includ-
ing the clinicians, who nevertheless considered their
clinical workload being a serious barrier to research.
One solution to this problem could be increasing rota-
tional positions for clinicians and researchers [8]. The high
standards of excellence in research are indicated by the
prevalence of previous research experience in a foreign
country, funding by competitive grants, publications in
international scientific journals, and international collabo-
rations. Most respondents are satisfied with the quality
and impact of the research performed in their institution,
and with the relevance of the research education programs
available in their university. Taken as a whole, these results
provide an encouraging picture of the research capacities
and activities in the MetabERN centres.
Research in the MetabERN centres is primarily per-
formed in the fields of genetics and pathophysiology.
There is strong focus on issues related to diagnosis. Pre-
dominant activities are studies of the genetic determi-
nants of diseases, the identification of new disease
entities, and the search of biomarkers for diagnosis and
prognosis. The constitution and the use of patient regis-
tries appear highly instrumental for these purposes [9,
10]. Consistently, responding teams are actively collabor-
ating with national and international patient registries in
their field of interest, and participate in the definition of
healthcare policies and guidelines, such as the imple-
mentation of new diagnostic technologies and the rec-
ommendations of the ISNS on issues related to neonatal
screening [11, 12]. Interestingly, as shown by their fre-
quent participation to the ERNDIM network, responding
teams demonstrate their interest for quality assurance is-
sues [13, 14]. It is however surprising in this context that
collaboration with the national and international bio-
banking platforms was rather infrequent [15]. The mar-
ginal interest for bioinformatics platforms is also noticeable,
suggesting that these infrastructures are not closely linked
with medical teams and/or not easily accessible [16].
Therapeutic research performed in the network es-
sentially consists in clinical research, with only modest
activity related to preclinical investigations. This find-
ing emphasizes the positioning of the MetabERN net-
work as a medical research network. Although links
with more basic biological research exist, as well as
projects involving omics technology, imaging, or animal
models, these activities are not central for the partici-
pating teams. The questionnaires were not intended to
collect detailed information on research activities based
on clinical trials, as this topic is treated in a currently
on-going study. Nevertheless, responses to the question
related to therapeutic research indicated that clinical
teams were all participating in clinical trials as a
current activity. Trials are most often investigational
studies, although participation to phase I/II and phase
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III clinical trials conducted by industrial companies is
also high.
A major finding of the survey is the limited implica-
tion of the respondents in human and social sciences
studies. Only one third or less of the respondents de-
clared having activity in this field, including research on
patient’s quality of life, patient’s awareness, or methods
for social support. This result points out that the multi-
disciplinary constitution of the responding teams is only
partial, and that they presumably often do not comprise
researchers in the field of human and social sciences.
This weakness may have practical consequences with re-
spect to the production of relevant knowledge for social
intervention, to the design of strategies aimed at
empowering patients and developing collaborations with
patient’s advocacy groups, and finally to ensure that pa-
tient’s needs are effectively taken into account. There-
fore, MetabERN should consider actions to be taken in
this field as an absolute priority [17]. In contrast to the
focus of EU policies on e-health and health technology
assessment, respondents declared modest implication in
these fields. As these are important issues for the imple-
mentation of the cross-border healthcare directive, it
would be worth encouraging teams to pay more atten-
tion to these matters.
Another unexpected result of the survey is the low
awareness of the respondents regarding services made
available by the international medical research infra-
structures, which have been set up by ESFRI. As many
of the proposed services would be highly instrumental
for the clinical research teams, this observation suggests
an important lack of sufficient communication and
knowledge transfer between the teams involved in ESFRI
infrastructure management and the teams involved in
medical research.
Conclusion
The survey points out the value of a transnational network
like MetabERN to carry out studies capable of giving a
broad and in-depth vision of the current status of medical
research in a specific field in Europe. The interpretation of
these results and the conclusions to be drawn will be
highly valuable for the design of research priorities in the
network, and might possibly influence research policies
on rare diseases beyond the network [18, 19].
Methods
The spectrum of HMDs cared for in the MetabERN cen-
tres can be specified according to the number and type
of patients they managed: AOAs count for 39% of the
activity (13,372 patients), LSDs 23% (7641), C-FAOs 16%
(5349), NOMS 11% (3848), PM-MD 7% (2414), PDs 3%
(994), and CDGs 1% (407). HCPs associated in the net-
work split their working time between various types of
activities, which in many cases are part of clinical care:
prevention and screening (9% of their time), diagnosis
and description of new disease entities (12%), patient
management and definition of guidelines and pathways
(12%), patient empowerment (10%), counseling (8.5%),
dissemination and contact with stakeholders (7%), edu-
cation and training (10%), research in epidemiology and
constitution of registries (12.5%), clinical research (10%),
and pre-clinical research (8%).
HCPs acting in the centres (n = 1671) form multidis-
ciplinary teams composed of specialized medical doc-
tors, many of them having teaching obligations (n = 871,
52%), biochemists/biologists (n = 188, 11%), pharmacists
(n = 34, 2%), nurses, dieticians, physical therapists and
psychologists (n = 454, 27%), social workers (n = 49, 3%),
managers, coordinators and secretaries (n = 75, 9%).
The survey was performed in December 2017/January
2018, asking the 69 MetabERN centres to complete ques-
tionnaires on the online SurveyMonkey platform. Consider-
ing the variety of the tasks directly or indirectly related to
providing care, teaching, or performing research on HMDs,
three different questionnaires were addressed to three dif-
ferent groups of actors in each centre: 1) a questionnaire
sent to the clinical department (61 questions) was supposed
to reach the persons involved in the various aspects of clin-
ical care; 2) a questionnaire sent to the University (37 ques-
tions) was aimed at collecting the views of researchers and
teachers; 3) a questionnaires sent to laboratories (37 ques-
tions) was intended to reach clinical biologists and pharma-
cists. Questionnaires included questions common to the
three groups and specific questions for each group. In total,
126 different questions were asked. Participants were in-
vited to answer questions with multiple choices. The list of
the questions sent to each group and the multiple choice
answers are shown as Additional file 1. Questions enquired
about personnel involved in research, quality and impact of
the research performed, motivation and barriers to do re-
search, research funding, level and type of research activity,
thematic priorities, access to and use of local, national and
international facilities and infrastructures. The responses
indicating “high” or “relatively high”, “very important” or
“important” were considered together and the correspond-
ing numbers of responses were added.
Additional file
Additional file 1: Table S1. List of the MetabERN centres and
participation to the survey (PDF 1220 kb)
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